Business Context and Reporting Period
Company: Dr. Reddy's Laboratories Limited (DRL)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Quarter and Six Months ended September 30, 2004
Currency: Indian Rupees (Rs.) with U.S. Dollar (U.S.$) convenience translation at Rs. 45.91 = U.S.$1.00
Business Overview: DRL is a pharmaceutical company engaged in the manufacture and sale of formulations, active pharmaceutical ingredients (APIs), generics, critical care products, and drug discovery. Operations are conducted globally with significant presence in India, North America, Europe, and Russia.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 2004 | Six Months Ended Sep 30, 2004 |
|---|---|---|
| Total Revenues | Rs. 5,407,368 (U.S.$ 117.8M) | Rs. 10,515,260 (U.S.$ 229.0M) |
| Gross Profit | Rs. 2,967,123 | Rs. 5,592,664 |
| Gross Margin | 54.9% | 53.2% |
| Operating Income | Rs. 475,235 | Rs. 519,054 |
| Net Income | Rs. 517,027 (U.S.$ 11.3M) | Rs. 690,449 (U.S.$ 15.0M) |
| Earnings Per Share (Basic) | Rs. 6.76 | Rs. 9.02 |
| Cash and Cash Equivalents (Sep 30, 2004) | Rs. 5,534,899 (U.S.$ 120.6M) | |
| Total Debt (Current + Long-term) | Rs. 1,466,304 (U.S.$ 31.9M) | |
| Net Cash from Operating Activities (6 Months) | Rs. 427,747 (U.S.$ 9.3M) |
Material Changes vs. Prior Period
- Revenue: Increased 0.6% quarter-over-quarter (QoQ) to Rs. 5.41 billion, driven by growth in international formulations and generics (Europe), offset by declines in North America and India.
- Net Income: Decreased significantly by 44.3% QoQ to Rs. 517 million. This was primarily due to a foreign exchange loss of Rs. 48.6 million (vs. a gain of Rs. 97.3 million in the prior year), increased operating expenses, and lower operating income.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses rose 17.5% to Rs. 1.73 billion due to higher employee and marketing costs. R&D expenses increased 27.8% to Rs. 626.6 million.
- Segment Performance:
- Formulations: Revenue up 17.5% QoQ, driven by strong growth in Russia (+63.0%) and other former Soviet Union countries.
- APIs: Revenue down 9.9% QoQ, largely due to a drop in Ramipril sales in Europe following a launch surge in the prior year.
- Generics: Revenue down 16.0% QoQ, impacted by price competition on Fluoxetine and Tizanidine in North America.
- License Fees: Recognized Rs. 235.55 million in license fees from Novartis during the six-month period following the expiration of a development agreement.
Guidance, Outlook, Risks, and Unusual Items
- Outlook: Management anticipates continued competition in the generics market, particularly for Fluoxetine and Tizanidine. The company plans to launch new products in the U.S. and U.K. and expand its pipeline. In the API segment, Ramipril sales are expected to stabilize at lower levels in fiscal 2005.
- Recent Developments:
- Novo Nordisk: On October 27, 2004, Novo Nordisk suspended clinical trials for two licensed molecules (ragaglitazar and balaglitazone). The accounting treatment for unamortized upfront fees is under evaluation.
- Biomed JV: Signed an agreement to sell its Russian joint venture, Biomed, for U.S.$5.0 million. A Moscow court injunction has temporarily halted the transfer of shares.
- Acquisition: Acquired Trigenesis Therapeutics, Inc. for Rs. 496.7 million (U.S.$11 million) in April 2004, accounted for as a purchase of intangible assets.
- Risks and Contingencies:
- Litigation (Norfloxacin): The Andhra Pradesh High Court dismissed DRL's appeal regarding price controls on Norfloxacin. DRL is appealing to the Supreme Court. Provisions have been made for excess sales proceeds; ultimate liability depends on the final court ruling.
- Patent Laws: India's transition to product patents (effective Jan 1, 2005) may limit new product launches and increase competition.
- Foreign Exchange: Significant volatility in the Indian Rupee against the U.S. Dollar impacted results, causing a loss on forward contracts.
Investor Verification Checklist
- Novo Nordisk Agreement: Verify the final accounting treatment for the unamortized license fees following the suspension of clinical trials for the two molecules.
- Biomed Sale: Monitor the status of the Moscow court injunction regarding the sale of the Russian joint venture and the expected closing date.
- Norfloxacin Litigation: Track the progress of the Special Leave Petition filed with the Supreme Court of India regarding price control provisions.
- Generics Competition: Assess the impact of ongoing price erosion on key U.S. generics (Fluoxetine, Tizanidine) and the success of new product launches.
- Foreign Exchange Exposure: Review hedging strategies given the material impact of Rupee depreciation on operating income.